Being a leading cause of death and disability worldwide, the only treatment available in the acute phase of stroke is thrombolysis with tissue plasminogen activator (tPA), a drug that can be administered to a low percentage of patients due to its narrow therapeutic window (<4.5 h) and safety concerns. Here, PLAT is linked to Stroke.